photo walkheader_zpsd5bunpmi.png

Category Archives: Pancreatic Cancer Medical Treatment

Cancer Diversity: Enemy of Personalized Medicine ?

In what appears to be a season of blockbuster conceptual research results in the cancer medical literature, comes a recent study involving leukemia cells but which has implications for the entire spectrum of cutting edge cancer treatment. The general current prevailing thought on the origin of cancer is that a pattern of gene mutations or […]

Biomarker miR-10b for Pancreatic Cancer: earlier diagnosis and/or therapeutic target?

As alluded to in another recent blog entry, the study of microRNA has been a source of great interest as to the possible development of biomarkers that may screen or aid on the diagnosis of pancreatic cancer (ductal adenocarcinoma of the pancreas).  MicroRNAs (or sometimes abbreviated miR) are small (18 to 25 nucleotide) non-coding RNA […]

SOX Chemo Regimen as 2nd Line for Pancreatic Cancer

Acronyms in medicine are often a hoot.  We have the four-drug combination called FOLFIRINOX for advanced pancreatic cancer (ductal adenocarcinoma of the pancreas).  Recently, here at Pancreatica we reported on a study of a three-drug version of the above termed: OFF.   Now comes a review of the regimen of S-1 plus oxaliplatin by Japanese researchers, […]

Page 8 of 11« First...678910...Last »